|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection显示文摘The systemic therapies available for the management of Psoriasis(PsO) patients who cannot be treated with more conservative options, such as topical agents and/or phototherapy, with the exception of acitretin, can worsen or reactivate a chronic infection. Therefore, before administering immunosuppressive therapies with either conventional disease-modifying drugs(c DMARDs) or biological ones(b DMARDs) it is mandatory to screen patients for some infections, including hepatitis B virus(HBV) and hepatitis C virus(HCV). In particular, the patients eligible to receive an immunosuppressive drug must be screened for the following markers: antibody to hepatitis B core, antibody to hepatitis B surface antigen(anti-HBs Ag), HBs Ag, and antibody to HCV(anti-HCV). In case HBV or HCV infection is diagnosed, a close collaboration with a consultant hepatologist is needed before and during an immunosuppressive therapy. Concerning therapy with immunosuppressive drugs in PsO patients with HBV or HCV infection, data exist mainly for cyclosporine a(Cy A) or b DMARDs(etanercept, adalimumab, infliximab, ustekinumab). The natural history of HBV and HCV infection differs significantly as well as the effect of immunosuppression on the aforementioned infectious diseases. As a rule, in the case of active HBV infection, systemic immunosuppressive antipsoriatic therapies must be deferred until the infection is controlled with an adequate antiviral treatment. Inactive carriers need to receive antiviral prophylaxis 2-4 wk before starting immunosuppressive therapy, to be continued after 6-12 mo from its suspension. Due to the risk of HBV reactivation, these patients should be monitored monthly for the first 3 mo and then every 3 mo for HBV DNA load together with transaminases levels. Concerning the patients who are occult HBV carriers, the risk of HBV reactivation is very low. Therefore, these patients generally do not need antiviral prophylaxis and the sera HBs Ag and transaminases dosing can be monitored every 3 mo. Concerning PsO patients with chronic HCV infection their management with immunosuppressive drugs is less problematic as compared to those infected by HBV.In fact, HCV reactivation is an extremely rare event after administration of drugs such as CyA or tumor necrosis factor-α inhibitors. As a rule, these patients can be monitored measuring HCV RNA load, and ALT, aspartate transaminase, gamma-glutamyl-transferase, bilirubin, alkaline phosphatase, albumin and platelet every 3-6 mo. The present article provides an updated overview based on more recently reported data on monitoring and managing PsO patients who need systemic antipsoriatic treatment and have HBV or HCV infection as comorbidity. | Claudio Bonifati Viviana Lora Dario Graceffa Lorenzo Nosotti | 2016 | World Journal of Gastroenterology2016，22，28： | 6 |
| 2 | Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma显示文摘AIM:To evaluate if indolent B cell-non Hodgkin's lymphoma(B-NHL) and diffuse large B-cell lymphoma(DLBCL) in hepatitis C virus(HCV) positive patients could have different biological and clinical characteristics requiring different management strategies.METHODS:A group of 24 HCV related B-NHL patients(11 indolent,13 DLBCL) in whom the biological and clinical characteristics were described and confronted.Patients with DLBCL were managed with the standard of care of treatment.Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed.The outcomes of the different approaches were compared.RESULTS:Patients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype.Five of the 9 patients with indolent HCV-relatedB-NHL treated with only antiviral therapy,achieved a complete response of their onco-haematological disease(55%).Seven of the 13 DLBCL patients treated with immunochemotheraphy obtained a complete response(54%).CONCLUSION:HCV genotypes and duration of HCV infection differed between B-NHL subtypes.Indolent lymphomas can be managed with antiviral treatment,while DLBCL is not affected by the HCV infection. | Adriano M Pellicelli Massimo Marignani Valerio Zoli Mario Romano Aldo Morrone Lorenzo Nosotti Giuseppe Barbaro Antonio Picardi Umberto Vespasiani Gentilucci Daniele Remotti Cecilia D'Ambrosio Caterina Furlan Fabrizio Mecenate Ettore Mazzoni Ignazio Majolino Roberto Villani Arnaldo Andreoli Giorgio Barbarini | 2011 | World Journal of Hepatology2011，3，11： | 4 |
| 3 | Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin’s lymphoma patients treated with immunochemotherapy显示文摘 | L. Nosotti M. D’Andrea A. Pitidis F. Pimpinelli M. L. Dessanti F. Pisani P. Vignally M. C. Petti | 2012 | Scandinavian Journal of Infectious Diseases2012，，1： | 2 |
| 4 | Muscle sparing versus postero- lateral thoracotomy for pulmonary lobectomy:randomised controlled trial显示文摘 | Nosotti M Baisi A Mendogni P | 2010 | Interact Cardiovasc Thorac Surg2010，5，11： | 1 |
| 5 | Muscle sparing versus postero- lateral thoracotomy for pulmonary lobectomy: randomised controlled trial显示文摘 | Nosotti M Baisi A Mendogni P | 2010 | Interact Cardiovasc Thorac Surg2010，11，4： | 1 |
| 6 | Quantitative real- time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinocmbryonic antigen marker 显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，3： | 1 |
| 7 | Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker 显示文摘 | Nosotti M Falleni M Pallesch A | 2005 | Chest2005，128，3： | 1 |
| 8 | Lymph node micrometastases detected by carcinoembryonic antigen mRNA affect long-term sur-vival and disease-free interval in early-stage lung cancer patients显示文摘 | Nosotti M Palleschi A Rosso L | | 0，，5： | 1 |
| 9 | Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，： | 1 |
| 10 | Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using careinoembryonic antigen marker显示文摘 | Nosotti M Falleni M Pallesehi A | 2005 | Chest2005，128，3： | 1 |
| 11 | Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer显示文摘 | Nosotti M Rebulla P Riccardi D | 2003 | Chest2003，124，1： | 1 |
| 12 | Role of 99Tcm-hexakis-2-methoxy-isobutylisonitrile in the diagnosis and staging of lung cancer显示文摘 | Nosotti M Santambrogio L Gasparini M | 2002 | Chest2002，122，4： | 1 |
| 13 | Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，3： | 1 |
| 14 | Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage Ⅰ lung cancer显示文摘 | Nosotti M Riccardi D Baisi A | | 0，，01： | 1 |
| 15 | Videothoracoscopy versus thoracotomy for the diagnosis of the indeterminate solitary pulmonary nodule显示文摘 | Santambrogio L Nosotti M Bellaviti N | 1995 | Ann Thorac Surg1995，59，4： | 1 |
| 16 | Quantitative real lung cancer micrometastasis using carcinoembryonic antigen marker 显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，3： | 1 |
| 17 | Quantitative real- time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen mark- er 显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，3： | 1 |
| 18 | Lymph node micrometastases detected by earcinoembryonic antigen mRNA affect long - term suiviv- al and disease - free interval in early - stage lung cancer patients 显示文摘 | Nosotti M Pallesehi A Rosso L | 2012 | Oneol Lett2012，4，5： | 1 |
| 19 | Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen markers 显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，3： | 1 |
| 20 | Quantitative Real-time Polymerase Chain Reaction Detection of Lymph Node Lung Cencer Micrometastasis using Carcinoemhryonic Antigen Marker显示文摘 | Nosotti M Falleni M Palleschi A | 2005 | Chest2005，128，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员